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Abstract
The endothelium is a thin monocelular layer that covers all the inner surface of the blood vessels, separating the circulating blood
from the tissues. It is not an inactive organ, quite the opposite. It works as a receptor-efector organ and responds to each
physical or chemical stimulus with the release of the correct substance with which it may maintain vasomotor balance and
vascular-tissue homeostasis. It has the property of producing, independently, both agonistic and antagonistic substances that help
to keep homeostasis and its function is not only autocrine, but also paracrine and endocrine. In this way it modulates the vascular
smooth muscle cells producing relaxation or contraction, and therefore vasodilatation or vasoconstriction. The endothelium
regulating homeostasis by controlling the production of prothrombotic and antithrombotic components, and fibrynolitics and
antifibrynolitics. Also intervenes in cell proliferation and migration, in leukocyte adhesion and activation and in immunological
and inflammatory processes. Cardiovascular risk factors cause oxidative stress that alters the endothelial cells capacity and leads
to the so called endothelial "dysfunction" reducing its capacity to maintain homeostasis and leads to the development of
pathological inflammatory processes and vascular disease.
There are different techniques to evaluate the endothelium functional capacity, that depend on the amount of NO produced
and the vasodilatation effect. The percentage of vasodilatation with respect to the basal value represents the endothelial
functional capacity. Taking into account that shear stress is one of the most important stimulants for the synthesis and release
of NO, the non-invasive technique most often used is the transient flow-modulate "endothelium-dependent" post-ischemic
vasodilatation, performed on conductance arteries such as the brachial, radial or femoral arteries. This vasodilatation is
compared with the vasodilatation produced by drugs that are NO donors, such as nitroglycerine, called "endothelium
independent". The vasodilatation is quantified by measuring the arterial diameter with high resolution ultrasonography. Laser-
Doppler techniques are now starting to be used that also consider tissue perfusion.
There is so much proof about endothelial dysfunction that it is reasonable to believe that there is diagnostic and prognostic value
in its evaluation for the late outcome. There is no doubt that endothelial dysfunction contributes to the initiation and
progression of atherosclerotic disease and could be considered an independent vascular risk factor. Although prolonged
randomized clinical trials are needed for unequivocal evidence, the data already obtained allows the methods of evaluation of
endothelial dysfunction to be considered useful in clinical practice and have overcome the experimental step, being non-invasive
increases its value making it use full for follow-up of the progression of the disease and the effects of different treatments.
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Ever since the endothelium was discovered by microscop-
ical examination, it has always been considered to be a
lining that acted as a barrier stopping intravascular coagu-
lation. Nevertheless, in the last decades, the recognition of
its multiple functions has shown it to be a true regulator
of blood flow and tissue homeostasis. Although it is a
monolayer that covers the inner surface of the entire vas-
cular system, its total weight is more than a liver and has
a mass equal to several hearts or, if it is extended, covers a
various tennis courts surface area. For these reason, it has
been postulated as the biggest and most important gland
of the body [1].
Anatomic and functional properties of the 
endothelial cell
Basically, the endothelial cell has the same characteristics
as all the cells of the human body; cytoplasm and
organelles surrounding a nucleus and contained by the
cellular membrane. The cell membrane is made of a dou-
ble layer of phospholipids separated by water compart-
ments and crossed by complex proteins that work as
receptor or ion channels. Various contractile proteins
cross the cytoplasm: actin, myosin, tropomyosin, α-actin
and others, that allow motor activities.[2] Some are organ-
ized as structures like the cortical web, the junction-asso-
ciated actin filament system related to the intercellular
unions and the striated myofibril-like filament bundles or
stress fibers (Figure 1).
The cortical web surrounds the internal surface of the sar-
colema and is responsible for the cells shape and elastic-
ity. It is sensitive to changes of the intravascular tension
and increases its stiffness with increases of the intravascu-
lar pressure. It also anchor's different membrane proteins,
among them annexine, which regulates endo- and exocy-
tosis, the E-selectins and cadherine, related to the adhe-
General organization of the cytoskeleton in vascular endothelial cells Figure 1
General organization of the cytoskeleton in vascular endothelial cells. From Drenckham D, Ness W.[2]Cardiovascular Diabetology 2006, 5:4 http://www.cardiab.com/content/5/1/4
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siveness of leukocyte and platelets. The adherence of these
elements and their passage through the endothelial cell
depends on the integrity of the cortical membrane.
The junction-associated actin filament system, known as FAU
system, is found in the intercellular space and its contrac-
tion and relaxation controls the dimension of the intercel-
lular space. In this way, it regulates the passage of solutes
and macromolecules between the blood and the sub
endothelial space. The Ca2+ concentrations, intracellular
second messenger and the common factor of the external
function of cells with intermittent or cyclic activities acti-
vate it, the energy is provided by adenosine tri-phosphate
(ATP). Pro-inflammatory cytokines, reactive oxygen spe-
cies, thrombin, platelet activating factor, an increase of
Ca2+ concentration in ischemic conditions, ATP exhaus-
tion and other toxic substances, alter the functions of the
junction-associated actin filament system and allow an
opening of the intercellular space and, with that, altera-
tion of the endothelial permeability. The FAU system is
closely related to the intercellular adhesion molecules,
especially with VE-cadherine maintaining a balance
between adhesive and contractile forces. Both cyclic ade-
nosine mono-phosphate (cAMP), originated through the
adenylate-cyclase, and the cyclic guanine mono-phos-
phate (cGMP), generated by a Ca2+-nitric oxide guanylate-
cyclase dependent pathway, are second messengers that
stabilize the FAU system and counteract the induction of
intercellular separation, which is done through a Ca2+-
dependent calmodulin. Nitrates, behave the same way.
Protein-kinase C (PKC) activation has the opposite effect
(Figure 2.)
Stress fibers are myofibril-like straight filament bundles
composed of actin filaments interspersed with myosin fil-
aments in a similar way as in striated muscle, and cross the
cytoplasm in all directions (Figure 1). The more pressure
and friction exerted by the circulating blood, the more
abundant they are. As all contracting tissues, their contrac-
tion and relaxation depend on the intracellular Ca2+ con-
centration and the presence of ATP, their principal
function is to adapt the shape of the cells to the mechani-
cal forces of blood flow and wall distention, reducing the
possibility of cellular lesions. When flow increases, so
does shear stress and the cells flatten and align in the
direction of blood flow, whereas, when flow decreases
shear stress does also, and the cells increase their volume
loosing their alignment, looking like cobble stones pav-
ing.
Morphological changes acquire importance in capillary
flow because they can slow or halt flow, as can be seen
under the effects of serotonine, histamine, noradrenaline
and trombine, although FAU also acts on this function. In
the capillary the blood cells are usually larger than the
diameter, but flow through the capillary by two main
mechanisms: a) by the flexibility and deforming capacity
of both type of cells, blood and endothelial cells, and b)
by the negative electrostatic charge both cells have and,
therefore, repel each other. Endothelial cells have a nega-
tive electrostatic charge because of the high concentration
of sialitic acid. If this concentration is diminished for any
reason, blood flow is disturbed.
The cell membrane is covered with flask-shaped mem-
brane invaginations, sometimes shaped like a pocket and
sometimes protruding out of the membrane, other times
flattened, undistinguished from the basic structure of the
cell membrane, but all of them very rich in lipids, sphin-
gomyelin, complex protein structures and multiple recep-
tors. These sites have been called "caveolae". They are so
abundant that it is estimated that they occupy between
5% and 10% of the total cell surface, and are presumed to
be cellular membrane receptor-efector areas.[3] In normal
circumstances there are various ways of transporting plas-
matic molecules through the endothelial barrier: a) inter-
cellular unions, that generally act as filters controlled by
the hydrostatic pressure that allow the passage of water
and dissolved substances; b) vesicles formed from the
"caveolae" that ease the passage of macromolecules
through the cell membrane and cytoplasm; and c) true
transcellular channels usually formed from various caveo-
lae that connect opposite sides of the cell membrane.
Through them, the endothelial regulates the passage of
fluid and macromolecules between the vascular and cellu-
lar compartments, when it fails in the venous capillary
area edema is produced, toxic and vasoactive substances
can cause this.
Intercellular cleft and occludens adherens junction in vascular  endothelial cells Figure 2
Intercellular cleft and occludens adherens junction in vascular 
endothelial cells. From Drenckham D, Ness W.[2]Cardiovascular Diabetology 2006, 5:4 http://www.cardiab.com/content/5/1/4
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Endothelial physiology
The endothelial cell behaves as a receptor-efector struc-
ture, that senses different physical or chemical stimulus
that occur inside the vessel, and therefor modify the vessel
shape or releases the necessary products to counter act the
effect of the stimulus and maintain homeostasis. The
endothelium is capable of producing a large variety of dif-
ferent molecules, as agonists as antagonists, therefore bal-
ancing the effects in both directions. Endothelium
produces vasodilators and vasoconstrictors, procoagu-
lants and anticoagulants, inflammatory and anti-inflam-
matory, fibrinolytics and antifibrinolytics, oxidizing and
antioxidizing, and many others (Figure 3) [1,6]. When
endothelial cell lose their ability to maintain this delicate
balance, the conditions are right for the endothelium to
be invaded by lipids and leukocytes (monocites and T-
lymphocytes). The inflammatory response is incited and
fatty streaks appear, the first step in the formation of the
atheromatous plaque. If the situations persist, fatty streaks
progress and the plaque are exposed to rupture and set the
condition for thrombogenesis and the vascular occlusion.
Nitric oxide
Nearly all stimuli that produce vasodilatation do it
through nitric oxide (NO), a volatile gas, biologically
active, present practically in all tissue and thanks to its low
molecular weight and its lipophilic properties it diffuses
easily across cell membranes. The NO crosses the
endothelial intima and reaches the smooth muscular tis-
sue of the arterial wall, and, through nitrosilation of the
hem from the guanylate-cyclase degrades the GTP releas-
ing cGMP, which in turn regulates the cytosolic Ca2+ and
causes smooth muscle fiber relaxation and therefore
vasodilatation [7].
NO is produced by the action of nitric oxide synthases
(NOS) on L-arginine aminoacid, producing NO and L-cit-
ruline, requiring O2 and Nicotinamide Adenine Dinucle-
otid Phosphate (NADP) coenzyme, essential in Redox
process. Tetra-hydro-biopterine accelerates this process,
which is favored by other cofactors like flavin-adenine
dinucleotide, and thiol groups like cysteine and reduced-
glutation. Three NOS isoenzimes are known, two consti-
tutives and low-production, NOS-I from neurological tis-
sue and NOS-III from endothelial cells, both respond to
agonist that increase intracellular Ca2+. The other one,
inducible NOS-II, is specially expressed in macrophage
and endothelial cells due to the effect of pro-inflamma-
tory cytokines and can release several times more NO than
the constitutives NOS. Both constitutives and inducible
NOS are in the endothelial cells. Constitutives NOS pro-
duces NO for short periods when it is induced by vasodi-
lators like acetylcholine or bradikinine. Inducible NOS
synthesize NO for longer periods in a constant manner
when the stimulus comes from pro-inflammatory
cytokines like tumor necrosis factor-α (TNF-α) [7,8].
The most important stimulation for NO release comes
from shear stress, that is caused by the increase in blood
velocity and leads to a vasodilatation proportional to the
amount of NO released by the endothelium [9]. This
vasodilatation is called endothelium-dependent. The
endothelial cell membranes contains specialized ion
channels, such as Ca2+-activated K+ channels, that open in
response to shear stress [10]. The effect is to hyperpolarize
the endothelial cell, increasing the driving force for Ca2+
entry and activates the enzyme NOS-III and the subse-
quent generation of NO [10]. Nitrates given in any way
are NO donors, unconfined NO into the circulation
directly releasing cGMP in the smooth muscle cell and
causing a vasodilatation that is not dependent of the
endothelial response, for this reason it is called endothe-
lium-independent vasodilatation. Shear stress induces a
persistent production of NO that maintains a constant
vasodilatation [11].
Shear stress explains the importance of the haemody-
namic factor in the formation, localization and plaque fis-
sure. This usually develops in areas were the shear stress is
low (<6 din/cm2), oscillating or retrograde, were NO
release is diminished and adhesion molecules are
increased and chemical and growth factors create a pro-
inflammatory atmosphere. On the other hand, a high
shear stress (>70 din/cm2) con cause endothelial erosion
and provoke platelet aggregation, or cause plaque rupture
or damage. That is to say that a low or retrograde shear
stress allows plaque formation and progression of the
Regulatory functions of the endothelium Figure 3
Regulatory functions of the endothelium. Normal or anti-
atherogenic vs dysfunction or atherogenic propierties. From 
Esper RJ, et al.[5]
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atherosclerotic lesion, and a high a shear stress causes
damage to the plaque. Physiological levels of shear stress
that protect the endothelium are between these two values
(6 to 70 din/cm2) [12-15].
NO apart of being a vasodilator, also reduces vascular per-
meability and the monocite and lymphocyte adhesion
molecules synthesis. NO also reduces platelet aggregation,
tissue oxidation, tissue inflammation, activation of
thrombogenic factors, cell growth, proliferation and
migration, also it inhibits proatherogenic and pro-inflam-
matory cytokines expression and it favors fibrinolysis.
Nuclear factor kappa-B (NFkB) inhibitor (I-kB) is also
expressed by NO. All these factors reduce atherogenesis
and its complication. For this reason NO is considered the
antiatherogenic molecule [16-22].
The endothelial cell releases angiotensin-II (AII) as an
antagonist of NO by means of hydrolyzing angiotensin-I
by angiotensine converting enzyme (ACE). Through AT1
receptor, AII  causes vasoconstriction and prothrombo-
genic, oxidizing and antifybrinolitic effects, and also
favors adhesion molecule expression and leukocyte adhe-
sion. Also it stimulates growth and proliferation factors,
activates inflammation and incite expression of pro-
inflammatory and proatherogenic cytokines. All these
effects allow atherosclerosis to start develop, progress and
complicate. Also AII  stimulates endothelin converting
enzyme that degrades big-endothelin releasing endothe-
lin-I, the most powerful vasoconstrictor on vessel walls
[23-25].
As can be seen, depending on the balance of these two
substances, NO and AII, a vasodilatation and antiathero-
sclerotic or vasoconstriction and atherogenic effect will
prevail. It is not necessary by increased production of one
or the other, the diminished synthesis of one, will make
normal amounts of the other prevail (Figure 3). The
endothelium should maintain an adequate homeostasis
so that the disease does not appear and this depends on
the capacity it has of producing the protective molecules.
When this function is lost or damaged, we refer to it as
"endothelial dysfunction" or "endothelial activation". The clas-
sical cardiovascular risk factors (hypercholesterolemia,
hypertension, smoking, diabetes, sedentary, etc.) and the
so called new risk factors like hiperhomocysteinemia,
lipoprotein Lp(a), infections by Chlamydia pneumoniae,
Helicobacter Pilorae, Cytomegalovirus, herpes zoster
virus or bacteroides gingivalis, all have a common factor
which is a state of oxidative stress that directly or through
heating proteins (HSP-60), stimulate NF-kB replication
that leads to the production of proatherogenic cytokines
like TNF-α, interleukins IL-1 and IL-6, adhesion mole-
cules and chemokines, that cause inhibition of ONS-III
activity and with that NO production, and favoring AII
synthesis and activity [26-30]. The pro-inflammatory
cytokines stimulate the replication of NF-kB that leads to
more cytokines production. Then inflammation amplify
inflammatory response [31].
It is useful to consider the other great source of vasodila-
tation, via arachidonic acid cascade that ends in prostaci-
clines, which release cAMP from ATP that regulates
cytosolic Ca2+, therefore producing relaxation and
vasodilatation. There are other vasodilatation mecha-
nisms, like endothelium derived hyperpolarizing factor
that increases the intracellular concentration of K through
CP450 cytochrome, and natriuretic peptide-C interven-
tion. It has recently been postulated that some ACE inhib-
itors stimulate endothelium derived hyperpolarizing
factor which would explain some beneficial effects these
compounds have that have not been satisfactorily
explained by ACE inhibition only. All these alternative
mechanisms are important in certain situations to substi-
tute NO deficit.
Endothelium and renin-angiotensin system
The Renin-Angiotensin System (RAS) is a cascade of enzy-
matic reactions that ends in AII. The renin, produced by
the kidney, acts on the angiotensinogen, produced by the
liver degrading it to AI, which in turn will be acted on by
circulating or tissue ACE and hydrolyzed to AII. Chymase,
Carboxypeptidase, Cathepsin G and Tonin can generate
AII from AI independently of ACE, and AII can also origi-
nate directly from angiotensinogen by non-renin
enzymes, such as tissue plasminogen activator (t-AP),
Cathepsin G and Tonin. Because of structural similarity
ACE also degrades other peptides that are substrates to
this enzyme such as P substance, enkephalins, neuro-
tensin, takynine and kininogen, the latter responsible for
bradykinin generation. Stimulates ONS-III, inducing ON
synthesis and prostacicline production, which in turn
have opposite the effects of AII. As can be seen, the inter-
relationship between agonists and antagonists is very
complex and requires a delicate balance which is the
endotheliums primary function [26-31]. There are two
RAS, one is circulatory and the other is in the tissues, the
latter at a cellular level develops approximately 90% of the
systems activity.
AII acts by stimulating specific receptors, in the human
body we are able to distinguish two different types of
receptors: AT1 and AT2. the AT1 receptors are responsible
for known effects of AII; vasoconstriction, increase of
aldosterone activity, myocardial hypertrophy, vessel wall
smooth muscle proliferation, renal sodium reabsortion,
increase in peripheral noradrenergic activity, vasopresin
release, sympathetic stimulation, decrease in renal blood
flow, etc. The effects of AT2 receptor stimulation is not
completely known, but there are animal and human dataCardiovascular Diabetology 2006, 5:4 http://www.cardiab.com/content/5/1/4
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that allow us to assume that they era responsible for apop-
tosis, a clear inhibition of proliferation, vascular endothe-
lial neogenesis stimulation and vasodilatation, all
opposite effects of AT1 [32]. AT2 receptors are found dur-
ing the last three months of pregnancy in the fetus, and
during the first three weeks of life. In adult tissues, they are
predominantly expressed in the brain and adrenals, with
lower levels expressed elsewhere [33]. They are expressed
when there is vascular injury.
There are different angiotensine peptides capable of stim-
ulating the AT1 receptors with varying intensity: AII(2–8),
AIV(3–8), AII(1–7). This fact and the different effects of
each one when the specific receptors were blocked suggest
that there are other specific receptors sensitive to each of
these peptides. In experimental animal models different
specific receptor variant have been isolated and cloned,
for example in the rat AT1A, AT1B, and AT1C. Nevertheless,
in human beings, only AT1 and AT2 receptors of ATII have
been identified. AII(1–7) has opposite effects of the classic
AII, producing vasodilatation, inhibiting proliferation,
myocardial hypertrophy and vascular smooth muscle pro-
liferation, and it is very unlikely that it should act through
the known AT1 and AT2 receptors. This led to believe that
there are specific receptors for it. This has actually been
reported recently although they have not yet been cloned
[32-34].
Oxidant byproducts and atherosclerosis
Oxidant products, such as superoxide anion (O2
-), hydro-
gen peroxide (H2O2), hydroxyl radical (HO), hypochlo-
rous acid (HOCl) and lipid radicals [33], are produced as
a consequence of normal aerobic metabolism. These mol-
ecules are highly reactive with other biological molecules
and are referred as Reactive Oxygen Species (ROS). Under
normal physiological conditions, ROS production is bal-
anced by an efficient system of antioxidants, molecules
that are capable to neutralize them and thereby prevent-
ing oxidant damage. In the tissues, naturally occurring
enzymatic antioxidants such as superoxide dismutase,
glutathione peroxidase, and catalase play an important
role in the conversion of ROS to oxygen and water. Several
nonenzymatic antioxidants, including the lipid-soluble
vitamin E and β-carotene and the water-soluble antioxi-
dants vitamin C, which particular protects plasma lipids
from peroxidation, scavenges superoxide anion, and plays
a role in recycling vitamin E [35]. In pathological states,
the ROS may be present in relative excess. This shift of the
balance in favor of oxidation termed "oxidative stress",
may have detrimental effects on cellular and tissue func-
tion. As mentioned before, cardiovascular risk factors gen-
erate oxidative stress (Table I).
LDL-cholesterol molecules are easily oxidized in a state of
oxidative stress, especially the small and dense molecules.
Native LDL molecules are innocuous, they do not produce
any inflammatory reaction and do not lead to foam cells
when phagocyte by specific native macrophage receptors.
Oxidized LDL-cholesterol molecules (LDL-ox), are highly
immunogenic, and is associated with up-regulation of
pattern-recognition receptors for innate immunity,
including scavengers receptors and toll-like receptors
[36,37]. They are found in all atherosclerotic lesions and
they generate antibodies that are capable of neutralizing
them. LDL-ox attack the arterial intima and leads to
release of phospholipids that can activate endothelial cells
[38], induces the production of endothelium adhesion
molecules and monocytes attraction [39], has endothe-
lium cytotoxic effect, increases proinflamatory gene activ-
ity and cellular growth factors, it provokes endothelial
dysfunction, platelet aggregation, metaloproteinase
expression and favors thrombogenesis [40]. LDL-ox mol-
ecules are found in the subendothelial layers and help to
activate monocytes that are transformed into macro-
phage, upregulating their scavenger receptors and toll-like
receptors that then phagocyte them. With progressive
accumulation of LDL-ox macrophage modulate their phe-
notype turning them into foam cells. Foam cells are the
principal component of the fatty streaks, first step in
atheromatous plaque formation, and they trigger anti-
genic reaction in T-lymphocytes that initiate or increase
the immunological response [41]. Also TNF-α is activated
and endothelial cell apoptosis is induced and has a close
relation with the severity of acute ischaemic syndromes
[42,43].
HDL cholesterol and apolipoprotein A-1 have direct
antiatherogenic and vascular protective effects. They have
antioxidant effects attributed to the binding of transition
metals and to the presence of paraoxonase, an enzyme
carried predominantely by apolipoproteins A-1 and J,
containing HDL particles, which has powerful antioxidant
effects. Morover, they have been shown anti-inflamma-
tory effects, scavenging of toxic phospholipids, stimula-
tion of reverse cholesterol transport, antithrombotic and
profibrinolytic effects, and attenuation of endothelial dys-
function [44].
The excess of ROS, especially superoxide anion, can oxi-
dize NO and transform it into peroxynitrite (ONOO), a
inactive molecule that can lead to more oxidation. This
situation is usually seen when ONS-II activation is
induced by the high concentration of NO it generates.
This also happens with high levels of LDL, especially small
and dense molecules that are prone to oxidation. Asym-
metric dimethyl-amino-arginine (ADMA) exists normally
in the body and it inhibits NO synthesis by competing
with L-arginine. In this way, reduce NO tissue concentra-
tion with all the consequences that this causes, to the
extent that many investigators consider it a new athero-Cardiovascular Diabetology 2006, 5:4 http://www.cardiab.com/content/5/1/4
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sclerotic risk factor. Serum levels of ADMA keep a close
relationship with LDL-ox concentration and viceversa
[45,46]. Peroxinitrite (ONOO) can oxidize tetra-hidro-
biopterin, a critical cofactor for ONS [47].
Long-term with most organic nitrates is frequently associ-
ated with a progressive reduction of hemodynamic effects.
Nitrates activates vascular NADPH oxidase with incre-
mental O2
- generations, and this highly reactive molecules
oxidize NO to ONOO [48]. Moreover, continuos treat-
ment with nitrates causes ONS-III dysfunction by oxida-
tive stress. Reduced bioavailability of tetra-hydro-
biopterin is involved in the pathogenesis of this phenom-
enon and is prevented by supplemental folic acid admin-
istration. ROS transform regular ONS-III function, and
produces O2
- in place of NO [49]. Oxidative stress may
explain the development of tolerance and the impaired
endothelial function during continuous organic nitrates
administration.
Inflammation and thrombosis
There is a clear relationship between inflammation and
thrombosis, each influencing the other. Inflammatory
cytokines induce procoagulant molecules in endothelial
cells such as von Willebrand factor, tissue factor and plas-
minogen activating inhibitor factors, PAI-1 and PAI-2.
Activated inflammatory cells also produce molecules that
contribute to the thrombogenesis such as tissue factor and
Thrombin, which in turn generates an intense mitogenic
stimulus and platelet activation [50-52]. Interleukin-6 not
only increase plasma concentration of C-Reactive Protein
(CRP) in the liver but also fibrinogen, PAI-1, and serum-
A amyloid protein. On the other hand, CRP amplify
immunological response inducing leukocyte adhesion
molecules and chemokines production in the endothelial
cells, and show synergetic action with bacterial polysac-
charides inducing monocyte grow factors [53]. Interleu-
quine IL-1 provokes synthesis of PAI-1 in the endothelial
cells whereas IL-4 induces plasminogen tissue activator (t-
PA) by monocytes. Cell surface-based signaling system
CD40L ligand (CD154), binding to its receptor CD40 on
the leucocyte, can induce tissue factor expression [50].
Platelets can express CD154, the molecule that regulates
tissue factor gene expression in the macrophage and
smooth muscle cells [51,52]. As can be seen, this process
is a complex feed-back in which inflammation favors
thrombosis, anti-inflammatory treatment has antithrom-
botic effects and viceversa [54,55].
Immunological system and atherogenesis
Atherosclerosis is related to activation of the immunolog-
ical system [56]. The developing atherosclerotic plaque
are infiltrated not only by macrophage but by T-lym-
phocyte (CD-4)Th called helper, and T-lymphocyte CD-8,
that suggest a specific immunological response [57].
Never the less investigators have not yet reached an agree-
ment on whether the effect is harmful or beneficial on the
developing plaque. T-lymphocytes (CD4)Th1 produce
TNF-α, Interferon-γ and IL-6, are all pro-inflammatory
compounds that activate macrophage and are responsible
for the late hypersensitivity reactions. On the other hand,
T-lymphocytes (CD-4)Th2 generate IL-4, IL-5, IL-10 and
IL-13, all of these anti-inflammatory molecules that pro-
mote antibody responses and energetically inhibit macro-
phage activity [58]. In the atherosclerotic plaque of
experimental animals and in human beings, inflamma-
tory cytokines produced by T-lymphocyte (CD4)Th1,
such as Interferon-γ and IL-12, have been found in a pro-
inflammatory surrounding similar to reumathoid arthritis
[59,62]. In other plaques they have not been detected, so
it is suspected that there is a reduction in the inflamma-
tory response which leads to the believe that the balance
between T-lymphocytes (CD-4)Th1 and Th2, may play an
important role in the progression or regression of the
plaque. In this respect statins play a role modulating
immunological activity [63-65].
Table 1: Normal aerobic metabolism oxidizing and antioxidizing systems
OXIDIZING SYSTEMS ANTIOXIDIZING SYSTEMS
Oxidant byproducts Enzymatic antioxidants
Superoxide Anion (O2
-) Superoxide dismutase
Hydrogen Peroxide (H2 O2) Glutathione peroxidase
Hydroxyl radical (HO) Catalase
Hypochlorous acid (HOCl)
Lipid radicals
Enzimatic oxidants Lipid-soluble antioxidants
Dehidrogenase Xantine Vitamin E
NADPH oxidase β-Carotene
Mieloperoxidase
Monoamino oxidase Water-soluble antioxidants
ON synthetase Vitamin CCardiovascular Diabetology 2006, 5:4 http://www.cardiab.com/content/5/1/4
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Sphingomyelinase is another immunological mediator
produced by macrophage and endothelial cell when stim-
ulated by inflammatory cytokines. It is one of the sub-
stances that are responsible for oxidized lipoproteins
passing through the endothelium, for foam cells forma-
tion and progression, and complication of the atheroscle-
rotic plaque [66,67].
From endothelial dysfunction to acute ischemic 
syndrome
Atherosclerosis has been considered as a disease of "four
concepts". In a substudy of 5.209 patients from the Fram-
ingham Study followed for 10 years, it was seen that those
patients with peripheral vascular disease had more proba-
bilities of having an Acute Myocardial Infarction (AMI) or
a Stroke, while those who had had an AMI had more pos-
sibilities of having a Stroke or peripheral vascular disease.
Also those who had suffered a Stroke had more chances of
having an AMI or peripheral vascular disease. From these
observation the first concept, that atherosclerosis is a diffuse
disease, was postulated [68,69].
The finding of lesions in different stages of development
throughout the body, and inclusive in the same territory,
lead to the second concept that "atherosclerosis is a hetero-
geneous and multiform disease" [69].
In advanced stages of arteriosclerosis, with stage IV and Va
by AHA classification or Ross type III lesion, two types of
lesions can be distinguished: I) Stable or fibrous plaque,
with a small and generally central lipid core protected by
a thick and resistant cover with a high content of collagen
and without signs of inflammation. These lesions usually
obstruct the vessel significantly and are easily seen by arte-
riography. II) High Risk, unstable or vulnerable plaque,
with a large lipid core usually eccentric, covered by a weak
and thin fibrous cap with little collagen and large quanti-
ties of macrophage and T-lymphocytes that are expression
of a great inflammatory reaction that seldomly occlude
the vessel significantly and is frequently not appreciated
by angiography. This has generated the third concept that
the "quality of the plaque is more important than the size", as
proved by the fact that these plaques rupture easily and
are responsible for the majority of the acute coronary syn-
dromes. According to a metaanalysis by Falk et al, these
high risk plaque which obstruct less than 70% and even
less than 50% usually are asymptomatic, they are not eas-
ily recognized and not considered significant by angiogra-
phy are responsible for 86% of acute coronary syndromes
[69-72].
In atherosclerotic disease classical risk factors play an
important part; high cholesterol serum levels, arterial
hypertension, smoking, obesity, sedentariness, and the so
called new risk factors such as hyperhomocysteinemia,
Lp(a) lipoprotein, Cytomegalovirus, Chlamydia pneumo-
niae, Helicobacter pilorae, Bacteroides gingivalis, genetic
factors (gene ECA, gene HLA and others), serum inflam-
matory markers (CRP, serum-A amyloid protein, and oth-
ers), and prothrombotic factors (PAI-I, D-dimer,
fibrinogen, von Willebrand, etc.), microalbumineamia,
all of these factors contribute, in different degrees, to
make acute coronary syndromes happen. This suggests the
fourth concept, that "atherosclerosis is an inflammatory,
immunological, polygenic and multifactorial disease" [72-77].
The evolution of the disease can be slow and patients with
risk factors develop chronic or unstable angina or AMI,
this form is observed in less than 40%, or it can develop
abruptly in patients who had low risk and were asympto-
matic when they develop unstable angina, AMI or sudden
death. This is found in more than 60% of patients and this
fact obliges us to find another explanation based on a new
physiopathological model.
All the experience obtained in the last years, suggests that
the endothelium's dysfunction is no only the initial stage
of the atherosclerotic disease that generates plaque forma-
tion, but also can causes plaque growth, and unprotected
the high risk plaque leading to develop a vascular event.
Between these two extremes endothelial dysfunction is
responsible for all the plaque growth, differences in
plaque development and plaque characteristics. For all
these reasons, endothelial dysfunction is one of the prin-
cipal mechanisms in atherosclerotic disease [78]. The
presence of classical and new risk factors generates a
chronic exogenous state of injury to the endothelium that
promotes abnormal response, vasoconstriction, accumu-
lation of inflammatory cells, migration of smooth muscle
cells, increased cytokine production, etc, all these factors
help atheromatous plaque formation and in turn generate
a negative feedback that leads to a second injury, this time
endogenous, that finally leaves the plaque unprotected
allowing it to rupture or erosion and triggering thrombo-
genic phenomena [79].
Diabetes and endothelium
Both type 1 (insulin-dependent) and type 2 (no insulin-
dependent) diabetic patients, have mostly been described
under enhanced oxidative stress, and both conditions are
known to be powerful and independent risk factors for
coronary heart disease, stroke, and peripheral arterial dis-
ease.
Hyperglycemia causes glycosylation of proteins and phos-
pholipids, thus increasing intracellular oxidative stress.
Nonenzymatic reactive products, known as Maillard or
browning reaction, glucose-derived Schiff base, and Ama-
dori products, form chemically reversible early glycosyla-
tion products which subsequently rearrange to form moreCardiovascular Diabetology 2006, 5:4 http://www.cardiab.com/content/5/1/4
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stable products, some of them on long-lived proteins (e.g.
vessel wall collagen) and continue undergoing complex
series of chemical rearrangements to form advanced glyc-
osylation end products (AGEs). Once formed, AGEs are
stable and virtually irreversible. AGEs generate ROS with
consequent increased vessel oxidative damage [80].
Phagocytes have specialized receptors for AGEs, their acti-
vation leading to oxidation of lipoproteins, especially the
phospholipid component in LDL, and stimulating an
immune-inflamatory response and a thrombogenic
response through Tromboxane A2  release and platelet
aggregation induction. Diabetic patients have increased
levels of inflammatory markers, including CRP, with
proinflammatory and proatherogenic properties.
The impressive correlation between coronary artery dis-
ease and alterations in glucose metabolism has raised the
hypotesis that atherosclerosis and diabetes may share
common antecedents. Large-vessel atherosclerosis can
precede the development of diabetes, suggesting that
rather than atherosclerosis being a complication of diabe-
tes, both conditions may share genetic and environmental
antecedents, a "common soil" [81].
Published data suggest that abnormal endothelial func-
tion precedes other evidence of vascular disease and that
the progresion of metabolic syndrome to type 2 diabetes
parallels the progression of endothelial dysfunction to
atherosclerosis. Both type 1 and type 2 diabetes, like met-
abolic syndrome and other cardiovascular risk factors
determine an abnormal endothelium response thought to
precede the development of atherosclerosis.
Lipoprotein-associated phospholipase A2 (LP PLA2)
The lipoprotein-associated phospholipase A2 (LP PLA2),
alternatively termed as platelet activating factor acetylhy-
drolase, is a calcium-independent phospholipase which
hydrolyzes specifically the short acyl groups at the sn-2
position of the phospholipid substrate. Thus LP PLA2
plays a key role in the degradation of proinflammatory
oxidized phospholipids (oxPL) and in the generation of
lysophosphatidylcholine (lyso-PC) and oxidized fatty
acids. LP PLA2 can also hydrolyze short-chain diacylglyc-
erols, triacylglycerols, and acetylated alkanols, and dis-
plays a PLA1 activity [82].
The LP PLA2 has been considered a risk marker for
endothelial dysfunction in diabetic patients. LP PLA2 lev-
els have show a significant and positive correlation with
CRP levels, reflecting the possible relation of LP PLA2
with inflammatory activity in atherosclerotic arteries [83].
Packard et al confirmed this previous data in a substudy of
the West of Scotland Coronary Prevention Study in which
they compared different inflammatory markers as cardio-
vascular risk predictors [84]. They found that in these
patients LP PLA2 levels had a strong, positive association
with the development of coronary events i.e., myocardial
infaction, cardiovascular death or revascularization proce-
dure, which was not confounded by other risk factors. The
patients in which LP PLA2 levels were in the highest quin-
tile had almost twice the risk of those in whom they were
in the lowest quintile [85].
Myeloperoxidase and Paraoxonase are other enzymes
involved in the evolution of endothelial dysfunction asso-
ciated with type-2 diabetes [86].
Erectile dysfunction, sildenafil and endothelial 
function
Erectile dysfunction is an important complication of car-
diovsascular disease and can work as a marker of endothe-
lial function as well as a predictor of elevated risk of
cardiovascular disease. About 30% of diabetic patients are
afected by it [87].
Ischaemic heart disease can contribute to erectile dysfunc-
tion usually through fear although it can also be the first
expression of coronary heart disease. Endothelial dysfunc-
tion is often found in patients with erectile dysfunction.
Erection is produced when erotic stimuli are percived by
diferent senses and reach the hypothalamus thus inhibit-
ing the simpathetic tone and releasing NO at the non
adrenergic and non colinergic nerve terminals and in the
endothelial cells of the penile arterioles. The NO reaches
the cavernous smooth muscle and the arteriolar wall acti-
vating the enzime guanylate cyclase that degrades GTP
releasing GMP, which reduces the smooth muscle Ca2+
uptake and produces vasodilatation. Phosphodiesterase-5
(PDE-5) reverts this situation by changing GMP back to
GTP. This enzime is found in the corpus cavernosum,
blood vessels and trachea, but not in the myocardium,
and is inhibited by sildenafil, that in this way prolongs
erection. Sildenafil is very highly selective for PDE-5 com-
pared to other PDE, so as to be considered to have a PDE-
5/PDE-3 selectivity ratio equal to 4000:1. This fact does
not allow sildenafil to have a measurable positive ino-
tropic effect on the myocardium [88].
Assessment endothelial function. Invasive and 
non-invasive techniques
Endothelial dysfunction, or loss or reduction of its capac-
ity of defense against proatherogenic factors, is obtained
evaluating any of the endothelium functions. For exam-
ple, quantifying circulating adhesion molecules, proather-
ogenic substances, antifibrinolytics, evaluation of serum
markers of inflammation, etc. All these are direct or indi-
rect markers the endothelium capacity to protect against
new atherosclerotic lesions or protect existing lesionsCardiovascular Diabetology 2006, 5:4 http://www.cardiab.com/content/5/1/4
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from causing a vascular event. Because of the ease with
which it can be done and its reliability, the most com-
monly used test in basic science and clinical research is
endothelial dependent vasodilatation modulated by flow,
considered at this moment the gold standard [78].
The first experiments to evaluate endothelial dependent
vasodilatation were performed by invasive techniques
catheterizing coronary arteries, were drugs that induced NO
release were injected, such as acetylcholine, metacholine,
papaverine, P substance, etc, and then measuring the per-
centage of vasodilatation. Ludmer et al [11], found that
injecting acetylcholine in normal coronary arteries pro-
duced endothelial dependent vasodilatation, were as in
coronary arteries with moderate or severe atherosclerotic
lesions a paradoxical vasoconstriction was obtained, indi-
cating that endothelial dysfunction was present. The par-
adoxical vasoconstriction is due to stimulation of the
muscarinic receptors of the smooth muscle cells by direct
acetylcholine action. It was also found that injecting nitro-
glycerine, an NO donor, there was always vasodilatation,
in this case considered endothelium independent vasodil-
atation. Vita et al [88], using the same method found that
the amount of coronary vasodilatation obtained by acetyl-
choline diminished in an inverse ratio with the increase of
total cholesterol or LDL-cholesterol levels. They also
observed that the presence of cardiovascular risk factors,
alone or combined, kept an inverse linear relationship
with the endothelium dependent vasodilatation response,
evidencing the additive effects on endothelial dysfunction
[88].
Later  forearm pletismography was used. This technique
could be considered partially invasive. It was performed
Flow mediated post-ischemic endothelial dependent vasodilatation Figure 4
Flow mediated post-ischemic endothelial dependent vasodilatation. Percent change in flow and diameter after occlusion. From 
Correti MC, et al.[93]Cardiovascular Diabetology 2006, 5:4 http://www.cardiab.com/content/5/1/4
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by placing the forearm in a pletismograph for veins
impedance and then injects the drug being studied, usu-
ally acetylcholine or metacholine, into the brachial artery.
Panza et al [89-91], studying hypertensive patients, found
them to have less vasodilatation response than normal
controls. Also, hypertensive patients had an increase in
vascular resistance in comparison with normotensive
patients, which was permitted by the endothelial dysfunc-
tion. As endothelium maintains a constant vasodilatation
level produced by NO, it was considered that in hyperten-
sion there was an endothelial dysfunction that reduced
NO release, and with that a reduced basal vasodilatation.
This led them to postulate that endothelial dysfunction
could be one of the causes of hypertension. Later on, other
working groups concluded that endothelial dysfunction
was probably a consequence and not the cause of hyper-
tension [88-91]. This technique mainly evaluates the
resistance arteries response.
In the last years, Celermajer et al [92], assessed the level of
vasodilatation by ultrasonography. This technique, non-
invasive and easy to repeat, by which due to the changes
that occur through time allow us to learn the natural evo-
lution of the disease or see the changes produced by the
different treatments given. Consists in causing forearm
ischaemia and observes the amount of post ischaemic
vasodilatation. Ischaemia is produced by compressing the
forearm by inflating a conventional cuff for measuring
blood pressure 30 mmHg above systolic pressure for five
minutes. When the pressure is released there is a marked
increase of flow to the forearm and this increases shear
stress which in turn stimulates NO release that causes
Flow mediated post-ischemic endothelium-dependent vasodilatation expressed as percent increase in arterial diameter (mean  ± SD) with respect to baseline values in hypercholesterolemic coronary artery disease patients under the effects of the statin  Simvastatin and the ECA inhibitor Enalapril, either separately or combined Figure 5
Flow mediated post-ischemic endothelium-dependent vasodilatation expressed as percent increase in arterial diameter (mean 
± SD) with respect to baseline values in hypercholesterolemic coronary artery disease patients under the effects of the statin 
Simvastatin and the ECA inhibitor Enalapril, either separately or combined. E: Enalapril, GI: Group I, GII: Group II, S: Simvas-
tatin. * p < 0.001 vs baseline, ‡ p < 0.01 vs Baseline, † p < 0.05 vs 8 weeks, § p < 0.001 vs 8 weeks. From Esper RJ, et al.[131]
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vasodilatation. The amount of vasodilatation is directly
proportional to the amount of NO released by the
endothelium and this allows us to evaluate endothelial
function. The increase in flow and vasodilatation is meas-
ured by high-resolution ultrasonography of the brachial
artery, and is expressed as a percentage of the increase of
the basal values [93,94]. It can also be performed on the
radial and femoral arteries [92,94]. This technique evalu-
ates mainly the conductance vessels, different from pletis-
mography that mainly evaluates the resistance vessels,
although both methods test NO release (Figure 4).
This method has shown a gradual decrease in the
endothelium dependent response depending on age, due
to gradual loss of NO synthesis by the endothelial cells
[95-97]. This same response is seen in patients with
atherosclerotic lesions whether symptomatic or asympto-
matic [97-99], in post-menopause women due to lack of
estrogen [100,101], and in presence of cardiovascular risk
factor such as hypercholesterolemia [102], hypertension
[103], active smoking [104,105], passive smoking [106],
obesity [107], diabetes [108], sedentariness [109], and
hyperhomocysteinemia [110]. Mild infections [111] and
increasing levels of CPR may also decrease de endothelial
response [112]. The reversal of the cardiovascular risk fac-
tors allows a better endothelial function increasing the
endothelial dependent vasodilatation which expresses an
increase in NO release. The reduction of serum cholesterol
levels [113-116], arterial pressure control [103,113], quit
smoking [94], weight control [107], diabetes improve-
ment [118], and physical activity [119] improving the
endothelial dependent response, indicating more ON
released. The administration of L-arginine, a NO precur-
sor, increases vasodilatation in patients with high choles-
Endothelium depended vasodilatation in no cardiovascular risk factor subjects and in patients with risk factors, hypercholester- olemia, smokers, within 24 hours of rapidly stabilized unstable angina, and approximately 30 days later, after pharmacological  treatment Figure 6
Endothelium depended vasodilatation in no cardiovascular risk factor subjects and in patients with risk factors, hypercholester-
olemia, smokers, within 24 hours of rapidly stabilized unstable angina, and approximately 30 days later, after pharmacological 
treatment. From Esper RJ, et al.[146]
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terol, coronary artery disease and heart failure [120-122].
As has been explained previously, all these risk factors act
by a common pathway, oxidative stress, with increased
production of ROS [124,125]. It has been observed that
giving anti oxidant vitamins C and E diminishes the pro-
duction of ROS [126-128], including when given before a
meal with a high fat content to reduce oxidation of post
absorption fatty acids and tryglicerydes [129], it is also
effective before smoking [130]. Recently it has been
reported that there is an additive effect with the simulta-
neous administration of a statin and ACE inhibitor in
hipercholesterolemic coronary artery disease patients
(Figure 5) [131].
The National Cholesterol Education Program (NCEP) rec-
ommends a maximum LDL cholesterol level of 160 mg/dl
in healthy population without risk factors, 130 mg/dl for
primary prevention, 100 mg/dl for secondary prevention
and 70 mg/dl for high risk patients. Nevertheless, Stein-
berg et al [132], have evaluated endothelial function in
healthy young patients with this technique without cardi-
ovascular risk factors and cholesterol levels between 146
and 195 mg/dl and LDL-cholesterol between 87 and 119
mg/dl, and found that the lower the total cholesterol and
LDL cholesterol levels, the better the vasodilatation
response, as an expression of better endothelial response,
which leads to the idea that the lower the cholesterol the
better the endothelial response [114].
Although the method of evaluating endothelial response
by measurements on the brachial artery is non-invasive
and easily repeated, without any risk for the patient, it is
time consuming and needs skilled and patient operators
[78]. With just a small displacement of the transducer the
results are altered. Some automated systems have shown
a reduction in the variation between operators
[78,133,134]. Some investigators have developed differ-
ent equipment to maintain the transducer in a constant
position. It is a well known fact that the response is differ-
ent whether the cuff is positioned on the arm or forearm.
Recently, an International task force published the guide-
lines for the techniques and assessment of this method
[94].
Looking for simpler methods of performing these proce-
dures laser-Doppler has recently been used. This tech-
nique considers the vasodilatation and the increase in
blood flow, evaluation tissue perfusion. It has the advan-
tage of being simple with immediate results and does not
need skilled operators [135,136].
Prognostic value of post-ischaemic flow 
mediated endothelium dependent 
vasodilatation
Although a lot has been published about post-ischemic
flow mediated endothelium dependent vasodilatation as
a test for endothelial function the same doubts remain:
can we compare the brachial artery with the coronary
artery?, and, does this technique have a prognostic value?.
The endothelial function of the brachial artery measured
by this method has shown a good correlation with the cor-
onary artery response at the same time and in the same
patient with acetylcholine and with other methods which
has led to consider the brachial artery as a "surrogate" of
the coronary artery [137,138]. It has also been shown at
necropsy that patients with grade I-III lesions in the left
descending coronary artery, had lesions of the same type
and severity in their brachial artery, confirming the simi-
larity [138]. Respect the sensibility of the method, using
7.5 Mhz or more transducers, modest changes of 0,1 mm
can be measured precisely and are easily reproduced
[78,94]. It has been shown that the inter-observer varia-
tion, with qualified observers is 0,1 mm [78,94].
With respect of the prognostic value, as this is a new
method, not enough time has elapsed for a proper evalu-
ation [139]. Never the less, an excellent correlation has
been noted with the severity of the vascular lesions, even
when they are asymptomatic and undetectable by the
usual clinical methods. It has also been reported that
patients without cardiovascular disease but with risk fac-
tors, had a brachial artery vasodilatation response dimin-
ished when compared with a normal population, and if
they had a peripheral artery disease the response was even
more diminished compared with the positive risk factor
population. This leads to the assumption that as the sever-
ity of the lesions increases, so does the endothelial dys-
function [140].
Some authors have related left ventricular mass with
endothelial function, and have reported that with normal
ventricular geometry, endothelial function was within
normal limits, were as in patients with concentric remod-
eling of the left ventricle showed a depressed endothelial
function, and in patients with concentric or eccentric left
ventricular hypertrophy the decrease of endothelial func-
tion was even greater [141]. The functional class by stress
test also has a close relation with endothelial function.
Those patients who reached 100 to 150 watts had a nor-
mal endothelial dependent vasodilatation similar to con-
trols, but if they reached 75 or less watts, the
vasodilatation response was depressed. The response to
nitroglycerine showed a similar response in both groups.Cardiovascular Diabetology 2006, 5:4 http://www.cardiab.com/content/5/1/4
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Schachinger, et. al. [142] in an average of 82 month fol-
low up, documented 14 major cardiovascular events, sud-
den death, AMI, unstable angina, stroke, or
revascularization procedures, in patients in the inferior
tertile of the vasodilatation response, and found 5 events
in the superior tertile of the population. Both the
endothelial dependent and endothelial independent
response and their ratio (EDV/EIV) were strongly related
to future cardiovascular events. Neunteufl et. al. [143] in
a long follow up, found that the depressed vasodilatation
response can predict the cardiovascular event risk for the
next 5 years. In patient with normal vasodilatation versus
abnormal vasodilatation, with a cut off at >10% in nor-
mal and <10% in abnormal response, the need for PTCA
or CABG differed significantly, with a greater tendency of
AMI in the patients with a poor response. Considering the
total event rates, the flow mediated post-ischaemic
endothelial vasodilatation response measured by high
resolution ultrasonography of the brachial artery showed
a sensitivity of 86% with a 51% specificity and a very
important negative predictive value of 93%.
Al Suwaidi et. al. [144] studied patients with mild coro-
nary artery disease (<30% stenosis) with quantitative cor-
onary angiography with a follow up of 8 months, and
found that patients with severe endothelial dysfunction
with acetylcholine had a significant increase of events,
14% when compared to patients with a normal or mildly
depressed vasodilatation response.
Schoeder et. al. [145] compared post ischaemic vasodila-
tation response of the brachial artery with the predictive
value of angina, stress test and radioisotope myocardial
perfusion. They found that this test had a sensitivity of
71%, a specificity of 81% and a positive predictive value
of 95%, similar values to the other three diagnostic tests.
Our group [146], found that endothelial dependant
vasodilatation during unstable angina is practically
absent, creating a doubt about whether "the endothelial
dysfunction is caused by the plaque rupture or if it existed
previously and did not protect the high risk atheromatous
plaque allowing the acute coronary event". Based on this
study and comparing with what happens to the ischaemic
myocardium, created the concept of "stunned" endothe-
lium to explain the low vasodilatation response in acute
ischaemia and "hibernated" endothelium when the poor
response is chronic, as observed with hypercholestero-
lemia and the presence of other risk factor (Figure 6).
Cohen et. al. [147] in a subgroup of patients taking part in
the CARE trial, studied the brachial artery vasodilatation
with ultrasound and found that post AMI patients treated
with statins and with cholesterol values considered "nor-
mal", had a significantly greater vasodilatation than the
group that received placebo. The magnitude of the
increase was correlated with the decrease of the LDL cho-
lesterol fraction. It has been considered that the improve-
ment of the vasodilatation response could be the main
mechanism of the reduction of recurrent events found in
the CARE trial.
It has been reported that non-invasive assessment of
endothelial function in the brachial artery predicts periop-
erative cardiovascular events in patients undergoing vas-
cular surgery [148]. In 1479 subjects attending a routine
exam at the Framingham Study, it has been shown that
advanced age and systolic blood pressure are strongly
associated with decreased endothelial function, and the
dilatation was larger in females vs males [149].
Ganz et al. discussed the pronostic value of the post-
ischaemic flow mediated endotelial vasodilatation in a
revision of the last 10 trials on the subject, and concluded
that is a useful diagnosis procedure with a high pronostic
value. In the same issue, in editorials by Verma et al, and
Willerson et al., arrived at similar conclusions [150-152].
The atherosclerotic lesion always starts with endothelial
dysfunction and progresses with the persistence of this
dysfunction [78,153-157]. From a practical point of view,
the established vascular lesions seen by angiography,
Intravascular Ultrasound (IVUS), Magnetic Nuclear Reso-
nance, Computed bean Tomography, Carotid ultrasonog-
raphy, etc, could be considered like the electrocardiogram
in ischemic heart disease, were as the techniques for
endothelial function evaluation would be similar to the
conclusions reached with stress tests, reassuring the
hypothesis that functional alterations precede the ana-
tomic lesions in the development of atherosclerosis and
the ischaemic cascade [156,157]. This idea is reinforced
by the relation between endothelial dysfunction and
microalbuminuria, another risk marker that is not often
taken into consideration [158].
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